Investment firm GI Partners closes Clinical Ink acquisition
Private equity investment firm GI Partners has announced the completion of the acquisition of global clinical trial technology firm Clinical…
Latest Deals
Investment firm GI Partners to acquire minority interest in Clinical Ink
Private equity investment firm GI Partners has announced that it will acquire a minority interest in global clinical trial technology…
Latest News
View More
Deciphera concludes target enrolment in GIST therapy trial
Deciphera Pharmaceuticals has concluded its target enrolment in the Phase III clinical study analysing its switch-control tyrosine kinase inhibitor, Qinlock (ripretinib), in patients with second-line…
Imago BioSciences expands myelofibrosis drug trial into Hong Kong
Biotechnology company Imago BioSciences has expanded its global Phase IIb clinical study evaluating bomedemstat (IMG-7289) into Hong Kong. Bomedemstat is an inhibitor of lysine-specific demethylase…
NeoImmuneTech initiates dosing in Covid-19 therapy trial
Clinical-stage biopharma company NeoImmuneTech (NIT) has dosed the first patient in its Phase I study analysing NT-I7 (efineptakin alfa) as…
FerGene’s Phase III NMIBC therapy trial meets primary endpoint
FerGene has published positive Phase III data from the US clinical trial analysing investigational gene therapy, nadofaragene firadenovec (rAd-IFN /…
MHI continues recruitment of non-hospitalised participants in Covid-19 trial
The Montreal Heart Institute (MHI) is continuing the COLCORONA clinical trial to recruit non-hospitalised adult patients with Covid-19 following a…
GoldenBiotech reports positive data from leukaemia drug trial
Taiwanese biopharma company Golden Biotechnology (GoldenBiotech) has reported that data from its Phase IIa clinical study conducted in Russia showed…
Latest Content
View MoreCabenuva (cabotegravir and rilpivirine) for the Treatment of HIV-1 Infection
Cabenuva is a complete antiretroviral regimen comprising Vocabria (cabotegravir) and Edurant (rilpivirine) for the treatment of HIV-1 infection in adult…
HLA-class-II/Factor VIII (FVIII) Peptidomic Variation in Dendritic Cells
Plasma-derived (pd) or recombinant (r) therapeutic factor VIII proteins (FVIIIs) are infused to arrest/prevent bleeding in patients with hemophilia A…
Nuedexta for the Treatment of Pseudobulbar Affect (PBA)
Nuedexta (dextromethorphan hydrobromide / quinidine sulfate) is a combination drug indicated for the treatment of pseudobulbar affect (PBA). The drug…